But the KFF Employer Health Benefits Survey shows that even though employers who said they offered obesity drug coverage grew from 18% in 2024 to 19% in 2025, those that said they didn't offer it also increased from 52% to 57% over the same period
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
8,8-Dimethyldihydroberberine (Di-Me, Fig
As of early 2025, a systematic review of the musculoskeletal literature identified 544 published BPC-157 articles from 1993 to 2024, of which 36 focused on orthopaedic outcomes and only one was a human clinical study [16]
Production is handled at Stevanato Groups FDA-inspected facility in Germany, providing customers with access to dedicated, established tooling and sub-assembly lines that can accommodate levels of customisation according to a customers production requirements
Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease